Abstract
Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.
| Original language | English |
|---|---|
| Pages (from-to) | 211-218 |
| Number of pages | 8 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2016 |
Fingerprint
Keywords
- Breast cancer
- ovarian function suppression
- premenopausal
- tamoxifen
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
Endocrine therapy in premenopausal women with breast cancer : A critical appraisal of current evidence. / Montemurro, Filippo; Del Mastro, Lucia; De Laurentiis, Michelino; Puglisi, Fabio.
In: Expert Review of Anticancer Therapy, Vol. 16, No. 2, 01.02.2016, p. 211-218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Endocrine therapy in premenopausal women with breast cancer
T2 - A critical appraisal of current evidence
AU - Montemurro, Filippo
AU - Del Mastro, Lucia
AU - De Laurentiis, Michelino
AU - Puglisi, Fabio
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.
AB - Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.
KW - Breast cancer
KW - ovarian function suppression
KW - premenopausal
KW - tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=84957430023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957430023&partnerID=8YFLogxK
U2 - 10.1586/14737140.2016.1128327
DO - 10.1586/14737140.2016.1128327
M3 - Article
VL - 16
SP - 211
EP - 218
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 2
ER -